{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T22:20:58Z","timestamp":1775341258407,"version":"3.50.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/bor.0000000000000284","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T05:43:23Z","timestamp":1457243003000},"page":"297-302","source":"Crossref","is-referenced-by-count":54,"title":["Treat-to-target as an approach in inflammatory arthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210128","first-page":"362","article-title":"Rheumatoid arthritis.","volume":"51","author":"Wright","year":"1944","journal-title":"Can Med Assoc J"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.1780270805","article-title":"Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years.","volume":"27","author":"Pincus","year":"1984","journal-title":"Arthritis Rheum"},{"key":"R3-16-20210128","first-page":"964","article-title":"Do drugs change the course of rheumatoid arthritis Br Med","volume":"280","author":"Wright","year":"1980","journal-title":"J"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-16-20210128","first-page":"2108","article-title":"The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients.","volume":"25","author":"Wolfe","year":"1998","journal-title":"J Rheumatol"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/1529-0131(199809)41:9<1571::AID-ART7>3.0.CO;2-R","article-title":"Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression.","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients.","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"key":"R8-16-20210128","first-page":"758","article-title":"A methodologic framework for developing and selecting endpoints in clinical trials.","volume":"9","author":"Tugwell","year":"1982","journal-title":"J Rheumatol"},{"key":"R9-16-20210128","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles.","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.43","article-title":"Efficacy of methotrexate in rheumatoid arthritis.","volume":"34","author":"Weinblatt","year":"1995","journal-title":"Br J Rheumatol"},{"issue":"suppl 31","key":"R11-16-20210128","first-page":"S178","article-title":"Methotrexate as the anchor drug for the treatment of early rheumatoid arthritis.","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R15-16-20210128","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/ard.2010.141234","article-title":"The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R16-16-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with second-line antirheumatic drugs: a randomized, controlled trial.","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/03009747709095448","article-title":"Effect of gold on progression of erosions in rheumatoid arthritis: better results with early treatment.","volume":"6","author":"Luukkainen","year":"1977","journal-title":"Scand J Rheum"},{"key":"R18-16-20210128","first-page":"1117","article-title":"Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians.","volume":"17","author":"McCarty","year":"1990","journal-title":"J Rheumatol"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/37.10.1084","article-title":"Diagnosis and course of early onset arthritis: results of a special early arthritis clinic compared to routine patient care.","volume":"37","author":"van der Horst-Bruinsma IE, Speyer","year":"1998","journal-title":"Br J Rheumatol"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/annrheumdis-2011-200315","article-title":"Immediate access rheumatology clinic: efficiency and outcomes.","volume":"71","author":"Gartner","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R21-16-20210128","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","article-title":"Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R26-16-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R27-16-20210128","first-page":"977","article-title":"The Diabetes Control and Complications Trial Research Group.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R28-16-20210128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11883-009-0039-1","article-title":"Moving toward new statin guidelines in a post-JUPITER world: principles to consider.","volume":"11","author":"Ridker","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"R29-16-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity.","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R30-16-20210128","first-page":"177","article-title":"Combination therapy in rheumatoid arthritis.","volume":"13","author":"Goekoop","year":"2001","journal-title":"Rheumatol"},{"key":"R31-16-20210128","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"R32-16-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of RheumatologyEuropean League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R33-16-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R34-16-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2012-201817","article-title":"In patients with early rheumatoid arthritis, the new ACREULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis.","volume":"72","author":"Sakellariou","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R35-16-20210128","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/annrheumdis-2012-201821","article-title":"Performance of the 2011 ACREULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.","volume":"72","author":"Thiele","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R36-16-20210128","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient reported outcomes and costs.","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R37-16-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force.","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R38-16-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R39-16-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R40-16-20210128","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","article-title":"A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.","volume":"71","author":"Schipper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R41-16-20210128","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/rheumatology\/keq195","article-title":"Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome.","volume":"49","author":"Schipper","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R42-16-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/acr.22010","article-title":"Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial.","volume":"65","author":"Pope","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R43-16-20210128","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/1471-2474-14-350","article-title":"Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.","volume":"14","author":"Vermeer","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"R44-16-20210128","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/ard.2010.141523","article-title":"Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study.","volume":"70","author":"Provan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R45-16-20210128","first-page":"369","article-title":"The separate impact of tight control schemes and disease activity on quality of life in patients with early rheumatoid arthritis: results from the CAMERA trials.","volume":"32","author":"Jurgens","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R46-16-20210128","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R47-16-20210128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"R48-16-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/rheumatology\/ker399","article-title":"Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years.","volume":"51","author":"Gullick","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R49-16-20210128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/rheumatology\/keu395","article-title":"Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).","volume":"54","author":"Sugihara","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R51-16-20210128","doi-asserted-by":"crossref","first-page":"A808","DOI":"10.1016\/j.jval.2015.09.092","article-title":"Cost reduction for a health system through decreasing number of eligible patients for biological therapy in patients with rheumatoid arthritis using the treat to target recommendations.","volume":"18","author":"Santos-Moreno","year":"2015","journal-title":"Value Health"},{"key":"R52-16-20210128","first-page":"1412","article-title":"Editorial: treat to target in rheumatoid arthritis: good for the joints as well as the heart Arthritis R","volume":"67","author":"Nurmohamed","year":"2015","journal-title":"heumatol"},{"key":"R53-16-20210128","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events.","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R54-16-20210128","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/ar2620","article-title":"Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.","volume":"11","author":"Pascual-Ramos","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R55-16-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13075-015-0697-z","article-title":"Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.","volume":"17","author":"Contreras-Yanez","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R56-16-20210128","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/03009742.2015.1043142","article-title":"Impact of physicians adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.","volume":"44","author":"Kuusalo","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"R57-16-20210128","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1136\/ard.2011.154179","article-title":"Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire.","volume":"70","author":"Haraoui","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"R59-16-20210128","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"R60-16-20210128","first-page":"S338","article-title":"Targeting ultrasound remission in early rheumatoid arthritis: results of the Taser study.","volume":"65","author":"Dale","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R62-16-20210128","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R63-16-20210128","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a posthoc analysis of the RAPID 1 trial.","volume":"39","author":"van der Heijde","year":"2012","journal-title":"J Rheumatol"},{"key":"R65-16-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","article-title":"Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support a consensus statement.","volume":"73","author":"Schoels","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R66-16-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R67-16-20210128","doi-asserted-by":"crossref","first-page":"528105","DOI":"10.1155\/2014\/528105","article-title":"Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.","volume":"2014","author":"Salaffi","year":"2014","journal-title":"Biomed Res Int"},{"key":"R68-16-20210128","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/annrheumdis-2012-203073","article-title":"Disparity between ultrasound and clinical findings in psoriatic arthritis.","volume":"73","author":"Husic","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R70-16-20210128","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"R71-16-20210128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T17:12:15Z","timestamp":1748797935000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201605000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000284","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}